No Data
No Data
RBC Capital Downgrades Zynex(ZYXI.US) to Hold Rating, Cuts Target Price to $5
RBC Cuts Price Target on Zynex to $5 From $5.50, Keeps Sector Perform Rating
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Zynex (ZYXI)
Zynex Medical Champions Noninvasive, Non-addictive Pain Management With NexWave | NASDAQ:ZYXI
Zynex, Inc.'s (NASDAQ:ZYXI) Popularity With Investors Under Threat As Stock Sinks 69%
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says